Harmony Biosciences Holdings (HRMY)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 78.56% | 79.74% | 82.70% | 83.66% | 84.01% | 86.06% | 84.62% | 84.66% | 84.56% | 85.17% | 93.20% | 93.23% | 92.95% | 94.12% | 83.35% |
| Operating profit margin | 26.87% | 26.06% | 28.27% | 34.80% | 35.01% | 39.28% | 30.81% | 29.48% | 28.68% | 26.41% | 34.49% | 34.56% | 32.55% | 28.15% | 23.99% |
| Pretax margin | 27.01% | 26.07% | 26.19% | 32.02% | 31.61% | 35.02% | 28.11% | 26.38% | 24.98% | 22.20% | 20.80% | 18.36% | 13.92% | 5.38% | 10.79% |
| Net profit margin | 20.49% | 18.23% | 18.25% | 23.53% | 23.49% | 29.69% | 42.02% | 41.98% | 43.30% | 40.63% | 18.16% | 16.74% | 12.87% | 4.93% | 9.94% |
The profitability ratios of Harmony Biosciences Holdings show variations over the reported periods. The gross profit margin has been relatively high, ranging from 78.56% to 94.12%, indicating that the company has maintained a healthy level of profitability after deducting the cost of goods sold.
The operating profit margin fluctuated between 26.06% and 39.28%, with highest values around the beginning and mid of the reporting period. This ratio reflects the company's efficiency in managing its operating expenses and is essential for assessing operational profitability.
The pretax margin, representing the proportion of earnings before taxes, varied between 5.38% and 35.02%. The consistent increase in this margin over the periods signifies the company's ability to generate profits before tax expenses.
The net profit margin, which indicates the proportion of revenue that translates into bottom-line profit, ranged from 18.23% to 43.30%. It shows the company's success in managing its expenses and generating net income.
Overall, Harmony Biosciences Holdings has demonstrated solid profitability ratios over the reporting periods, with fluctuations seen in some margins. The company's ability to maintain healthy profitability margins is crucial for sustained financial performance and investor confidence.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 19.10% | 18.89% | 20.75% | 24.04% | 23.67% | 25.64% | 19.32% | 18.61% | 17.84% | 15.73% | 21.85% | 21.67% | 20.19% | 17.04% | 15.56% |
| Return on assets (ROA) | 14.56% | 13.21% | 13.40% | 16.26% | 15.88% | 19.38% | 26.34% | 26.50% | 26.93% | 24.19% | 11.51% | 10.49% | 7.98% | 2.99% | 6.45% |
| Return on total capital | 23.73% | 23.49% | 25.69% | 30.12% | 29.75% | 30.06% | 22.06% | 21.18% | 20.29% | 18.97% | 25.29% | 24.86% | 23.25% | 19.49% | 17.38% |
| Return on equity (ROE) | 22.07% | 20.55% | 21.35% | 26.72% | 27.59% | 31.32% | 41.27% | 42.77% | 45.05% | 45.27% | 23.57% | 22.70% | 18.55% | 7.68% | 18.34% |
Harmony Biosciences Holdings has demonstrated a generally positive trend in profitability ratios over the analyzed period.
- Operating return on assets (Operating ROA) has shown an upward trajectory, starting at 15.56% in June 2021 and peaking at 25.64% in September 2023, before settling at 19.10% as of December 2024.
- Return on assets (ROA) also displayed an overall increasing trend, with a significant rise from 2.99% in September 2021 to a peak of 26.93% in December 2022. It slightly decreased to 14.56% by December 2024.
- Return on total capital exhibited fluctuations but generally improved over time, reaching the highest level of 30.12% in March 2024 after starting at 17.38% in June 2021.
- Return on equity (ROE) displayed a similar pattern, with a notable increase from 7.68% in September 2021 to a peak of 45.27% in September 2022. The ratio then gradually declined to 22.07% by December 2024.
Overall, Harmony Biosciences Holdings' profitability ratios reflect a positive performance, as indicated by the increasing trends in most metrics. The company's ability to generate returns from assets, capital, and equity has generally improved over the analyzed period, suggesting effective management of resources and a strengthening financial position.